Candida antigen in the treatment of basal cell carcinoma

Kent Aftergut, Mary Curry, Jack Cohen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.

Original languageEnglish (US)
Pages (from-to)16-18
Number of pages3
JournalDermatologic Surgery
Volume31
Issue number1
StatePublished - Jan 2005

Fingerprint

Basal Cell Carcinoma
Candida
Antigens
Immunotherapy
Therapeutics
Skin Neoplasms
Neoplasms
Placebos
Safety
Control Groups
Injections

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Candida antigen in the treatment of basal cell carcinoma. / Aftergut, Kent; Curry, Mary; Cohen, Jack.

In: Dermatologic Surgery, Vol. 31, No. 1, 01.2005, p. 16-18.

Research output: Contribution to journalArticle

Aftergut, K, Curry, M & Cohen, J 2005, 'Candida antigen in the treatment of basal cell carcinoma', Dermatologic Surgery, vol. 31, no. 1, pp. 16-18.
Aftergut, Kent ; Curry, Mary ; Cohen, Jack. / Candida antigen in the treatment of basal cell carcinoma. In: Dermatologic Surgery. 2005 ; Vol. 31, No. 1. pp. 16-18.
@article{a56dfe92be2c47ca9566d0d6d1231139,
title = "Candida antigen in the treatment of basal cell carcinoma",
abstract = "BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56{\%}) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.",
author = "Kent Aftergut and Mary Curry and Jack Cohen",
year = "2005",
month = "1",
language = "English (US)",
volume = "31",
pages = "16--18",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Candida antigen in the treatment of basal cell carcinoma

AU - Aftergut, Kent

AU - Curry, Mary

AU - Cohen, Jack

PY - 2005/1

Y1 - 2005/1

N2 - BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.

AB - BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.

UR - http://www.scopus.com/inward/record.url?scp=11844275239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844275239&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 16

EP - 18

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 1

ER -